The comparison of the alterations in signaling pathways among breast cancers at different stages revealed the mutations in the p53 pathway were markedly enriched in more advanced breast cancer, e.g., stages III and IV (Supplementary Fig. 8c). This evidence concerns the gene TP53 and breast carcinoma.